Oncology has seen incredible growth over the past decade, not only in terms of the number of products being developed, but also in terms of new modalities that have introduced incredible diversification into the pipeline.

Scrip, in partnership with PCI Pharma Services, surveyed top decision makers across pharma for their views on oncology R&D and the role of outsourcing within it. Discover what the survey revealed, from which services are most frequently outsourced to what the future of oncology products holds, in your free research report, “How The Transformation Of Oncology R&D Is Reshaping Outsourcing.”